Impetigo
Conditions
Keywords
p-menthane-3,8-diol oil extract, topical therapy
Brief summary
This study aims to investigate the efficacy and safety of topical p-menthane-3,8-diol (PMD)-rich Corymbia Citriodora oil (Citriodiol®) in children with impetigo. Citriodiol® is already known to be effective as an insect repellent and is safe in its topical application. The investigators have also found in our laboratory that it is bactericidal against Staphylococcus aureus, the bacteria responsible for causing impetigo. Parents are always searching for a natural alternative to antibiotics (the current gold standard treatment for impetigo), and the investigators believe Citriodiol® could provide this possible alternative.
Detailed description
The extract of lemon eucalyptus, a common plant, has since the 1970s been used in commercial insect repellent products. Recently, it has been shown that lemon eucalyptus has potent anti-bacterial and anti-fungal effects that should assist in the treatment of inflammatory conditions such as impetigo. Our aim is to investigate this further by investigating the safety and efficacy of this product in the treatment of Impetigo. A randomised, double-blinded, three-armed pilot study, involving a total of 30 patients will be recruited from the dermatology outpatient department clinic at Royal North Shore hospital for this study. These patients will be between the ages of 12 months and 12 years with a clinical diagnosis of Impetigo. The three treatment groups will include a 2% or 5% topical p-menthane-3,8-diol (extracted from lemon eucalyptus) and a topical Mupirocin arm, which will be applied topically twice a day till resolution of symptoms. Follow-up will occur weekly until resolution of symptoms, which is expected within 2 weeks. Photographs, disease severity assessment and lesional swabs for culture will be taken at recruitment and as progress.
Interventions
DRUGp-menthane-3,8-diol oil
Apply topically to affected area twice daily
Sponsors
Royal North Shore Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
12 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
* age between 12 months and 12 years * dermatologist-confirmed impetigo * written informed consent provided by parents
Exclusion criteria
* impetigo requiring oral/systemic therapy * diagnosis of another form of staphylococcal or streptococcal disease (eg, cellulitis, erysipelas, abscess) * serious local infection (eg, cellulitis, abscess, wound infection) or systemic infection * oral or topical antibiotics * known allergy to topical insect repellents * patients receiving systemic corticosteroids, immunosuppressive agents, radiation therapy, chemotherapy within 1 month prior to entry into study * history of any clinically significant or poorly controlled cardiac, haematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, and/or other major disease as determined by the investigator * current enrollment in any other trial of an investigational drug within 30 days prior to study drug administration * other unspecified reasons, in the opinion of the investigator that makes the patient unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in severity score of impetigo | 2 weeks |
Countries
Australia
Contacts
Primary ContactShreya Dixit, B Med Sci, MBBS (Hons)
Backup ContactGayle Fischer, MBBS (Hons), FACD
Outcome results
None listed